Absolute Bioavailability and ADME study of [14C]AZD9977 in Healthy Male Subjects

Study identifier:D6402C00002

ClinicalTrials.gov identifier:NCT04686591

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study of Absolute Bioavailability and Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]AZD9977 in Healthy Male Subjects

Medical condition

cardiovascular disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq), AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

Sex

Male

Actual Enrollment

8

Study type

Interventional

Age

30 Years - 60 Years

Date

Study Start Date: 21 Dec 2020
Primary Completion Date: 04 Feb 2021
Study Completion Date: 04 Feb 2021

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Quotient Sciences Limited

Inclusion and exclusion criteria